Adial Pharmaceuticals (ADIL) Non Operating Income (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Non Operating Income of -$20911.0 for Q1 2026, up 68.75% sequentially from -$66925.0 in Q3 2025, and down 154.33% YoY from $38492.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Non Operating Income (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Non Operating Income for 10 years, with the latest figure at -$20911.0 in Q1 2026.
- Quarterly Non Operating Income fell 154.33% year-over-year to -$20911.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$250284.0 (up 97.38% YoY) and the FY2025 annual result came in at -$177709.0, up 96.38% from the prior year.
- Non Operating Income advanced to -$20911.0 in Q1 2026 per ADIL's latest filing, from -$66925.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $151115.0 in Q1 2022 and troughed at -$4.8 million in Q3 2024.
- A 5-year average of -$687160.9 and a median of -$8719.5 in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income soared 2200.08% in 2022, then slumped 46826.6% in 2024.
- Over 5 years, Non Operating Income stood at $47821.0 in 2022, then slumped by 78.6% to $10236.0 in 2023, then plunged by 46826.6% to -$4.8 million in 2024, then soared by 98.6% to -$66925.0 in 2025, then jumped by 68.75% to -$20911.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$20911.0, -$66925.0, and -$200940.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,911.00 |
| Sep 30, 2025 | -66,925.00 |
| Jun 30, 2025 | -200,940.00 |
| Mar 31, 2025 | 38,492.00 |
| Sep 30, 2024 | -4.78 Mn |
| Jun 30, 2024 | -171,487.00 |
| Mar 31, 2024 | -4.63 Mn |
| Sep 30, 2023 | 10,236.00 |
| Jun 30, 2023 | -32,475.00 |
| Mar 31, 2023 | 28,892.00 |
| Dec 31, 2022 | 47,821.00 |
| Sep 30, 2022 | 3,472.00 |
| Jun 30, 2022 | 6,930.00 |
| Mar 31, 2022 | 151,115.00 |
| Dec 31, 2021 | 56,215.00 |
| Sep 30, 2021 | -254,256.00 |
| Jun 30, 2021 | -37,209.00 |
| Mar 31, 2021 | 6,570.00 |
| Dec 31, 2020 | 1,349.00 |
| Sep 30, 2020 | 2,532.00 |